Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Metabolic Syndrome in Female Schizophrenia
NCT03251716Completed
- Sponsor
- Tianjin Anding Hospital
- Start
- Jan 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of berberine in metabolic syndrome, sponsored by Tianjin Anding Hospital. Primary endpoint: Change of Fasting Blood Glucose at 8 weeks. Started Jan 2015; status: completed.
02
Drugs
berberine
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT03251716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251716.